SCHEMBL6030484

SCHEMBL6030484

CCCCCCCCNC(=O)Nc1sc(C(=O)OCc2ccccc2)c(C)c1C(=O)O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.48
POLB P06746 2/20 0.48
EPHX1 P07099 6/20 0.48
ALDH1A1 P00352 4/20 0.48
HTT P42858 1/20 0.48
TSHR P16473 3/20 0.44
MEN1 O00255 1/20 0.43
HPGD P15428 1/20 0.43
KMT2A Q03164 1/20 0.43
BRAF P15056 1/20 0.42
RAB9A P51151 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
SIRT2 Q8IXJ6 5/20 0.42
SIRT1 Q96EB6 3/20 0.42
SIRT3 Q9NTG7 3/20 0.42
EPHX2 P34913 1/20 0.42
CYP3A4 P08684 1/20 0.41
MAPK1 P28482 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6029449 0.90 MAPT (0.52) MAPTPOLBALDH1A1TSHRHPGD
SCHEMBL6030356 0.90 MAPT (0.45) MAPTPOLBEPHX1ALDH1A1HTT
SCHEMBL6031521 0.90 MAPT (0.45) MAPTPOLBEPHX1ALDH1A1HTT
SCHEMBL6031142 0.90 MAPT (0.45) MAPTPOLBEPHX1ALDH1A1HTT
SCHEMBL6029684 0.90 MAPT (0.45) MAPTPOLBEPHX1ALDH1A1HTT
SCHEMBL6208748 0.89 EPHX1 (0.47) MAPTPOLBEPHX1ALDH1A1HTT
SCHEMBL6030266 0.89 EPHX1 (0.43) MAPTPOLBEPHX1ALDH1A1HTT
SCHEMBL6030263 0.88 EPHX1 (0.43) MAPTPOLBEPHX1ALDH1A1HTT
SCHEMBL6029736 0.86 ALDH1A1 (0.48) MAPTPOLBEPHX1ALDH1A1HTT
SCHEMBL6031228 0.86 MAPT (0.47) MAPTPOLBALDH1A1TSHRMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7064122-B2 Pancreatic lipase inhibitor compounds, their synthesis and use OSI PHARMACEUTICALS, INC. (US) 2006-06-20 US disclosed
US-20030195199-A1 Pancreatic lipase inhibitor compounds, their synthesis and use OSI PHARMACEUTICALS, INC. 2003-10-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030195199-A1 Pancreatic lipase inhibitor compounds, their synthesis and use PNLIP, LIPC, CEL MAPT 4105/4885POLB 2788/4885EPHX1 938/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.